Orphan Medical Licenses Cataplexy Treatment to Celltech
By Business Review Editor
Pharma Deals Review: Vol 2003 Issue 42 (Table of Contents)
Published: 3 Dec-2003
DOI: 10.3833/pdr.v2003.i42.847 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Orphan Medical licensed the European sales and marketing rights for its central nervous system depressant, Xyrem® (sodium oxybate) for treating cataplexy to Celltech Pharmaceuticals...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS